Valence is committed to unlocking the true potential of deep learning in drug design. By combining novel deep learning technologies with intuitive infrastructure to enable integration into R&D organizations of all sizes, Valence is empowering drug discovery scientists everywhere with the tools they need to design better drug candidates, faster.
The company's platform uses bioinformatics and artificial intelligence to optimize the development of drugs through predictive analytics and work with the small and noisy datasets characteristic of low-throughput compound screens and late-stage lead optimization, enabling pharmaceutical companies to reduce the time, design, and optimize novel ligands against a broad range of precision medicine targets.
Total Funding: $1.5 M
Funding Stage: Pre-Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2018
Apr 2021
- Partnering with Charles River to Democratize AI-Enabled Drug Design
Mar 2021
- Valence Announces Multi-Target Drug Design Collaboration with Servier
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Valence Discovery
ML Research Scientist
Montreal , Quebec
Computational Chemist
Montreal , Quebec
Head of Chemistry / Drug Discovery
Montreal , Quebec
Head of Discovery Biology
Montreal , Quebec
Sr ML Infrastructure Engineer
Montreal , Quebec
